drugset / Trial / NCT03779451
Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate in Placenta Previa
RandomizedParallel-groupOpen-labelPrevention
Summary
Purpose to evaluate the effects of Vaginal Progesterone versus 17-Alpha-Hydroxyprogesterone Caproate for prevention of Emergent Cesarean Delivery in Asymptomatic Pregnant Women with Placenta Previa
Timeline
- Start
- 2019-01-01
- Primary completion
- 2021-12-31
- Completion
- 2022-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | 17-alpha-hydroxyprogesterone caproate | Unknown | 250 mg | Intramuscular |
| Comparator | Progesterone | Other / unclassified | 400 mg | — |